segunda-feira, outubro 16, 2017

"Value over volume"

Há dias criticavam a União Europeia por esta querer relacionar o aumento do número de professores com a melhoria dos resultados dos alunos.

Onde é que já se viu tamanha enormidade?! (Estou a ser irónico)

Eis o futuro na saúde, também:
"Doctors and hospitals are increasingly being paid not for the quantity of care they provide, but for the outcome or quality of care patients receive. The emerging trend in health care is about rewarding value, rather than volume. This is the future, where there is less focus on the number of tests or treatments a patient receives and more focus on whether a patient’s health is improving.
...
Roughly 20 agreements have been announced in recent months, and each is developed with differing details. For example, some result in larger rebates or lower prices if a drug does not lead to its intended results. Other arrangements let patients “try before you buy” and only require payment if the therapy works. Still others promote “pay for performance” in which a drug’s cost is tied to its effectiveness....While nearly 90 percent of all drugs on the market are low-cost generic medicines, roughly 5 percent of patients take so-called “specialty” drugs to treat serious or life-threatening diseases. These drugs represent one-third of all drug spending, and this trend is expected to continue with the discovery of new treatments for rare diseases and other highly personalized medicines."
Trechos retirados de "The future of drug pricing: Value over volume"

Sem comentários: